BeStock  

Evotec EVO

US equityMarket cap rank #3614Drug Manufacturers - Specialty & Generic
$1.32 −$0.13 (-8.97%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $1.34 +1.52%
Open$1.38
Prev close$1.45
Day range$1.32 – $1.38
Volume77.6K
Market cap$469.11M
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±6.8%last 16 reports
Closed higher8 of 1650% of the time
Best reaction+13.1%
Worst reaction-15.7%

Stock move on the day after each report

+5.7%2023/Q2+6.6%2023/Q3+1.6%2024/Q1-0.3%2024/Q2-15.6%2024/Q3+10.1%2024/Q4-2.9%2025/Q1+0.0%2025/Q2-15.7%2025/Q3+1.3%2026/Q1-7.8%2026/Q2+13.1%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q35 Nov 2026None–+13.06%–
2026/Q213 Aug 2026Pre Market–-7.76%–
2026/Q16 May 2026Pre Market–+1.25%–
2025/Q35 Nov 2025Pre Market–-15.74%–
2025/Q213 Aug 2025None–+0.00%–
2025/Q16 May 2025Pre Market–-2.88%–
2024/Q417 Apr 2025Pre Market–+10.09%–
2024/Q36 Nov 2024Pre Market–-15.61%–
2024/Q214 Aug 2024Pre Market–-0.30%–
2024/Q122 May 2024Pre Market–+1.57%–
2023/Q38 Nov 2023None–+6.55%–
2023/Q229 Aug 2023None–+5.68%–
2022/Q428 Mar 2023Pre Market–+5.19%–
2022/Q39 Nov 2022None–-10.39%–
2022/Q211 Aug 2022None–+0.08%–
2022/Q111 May 2022None–-13.23%–

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q1

By business line

  • Discovery & Preclinical Development (D&PD)€119.90M 76.5%
  • Just - Evotec Biologics (JEB)€36.84M 23.5%

Latest reported quarter: Q3, ended Sep 2026 · reported in EUR

Revenue€164.93M+0.6% YoY
Operating profit-€27.12M+39.2% YoY
Net profit-€26.74M+37.9% YoY
Diluted EPS-€0.08+37.5% YoY
Free cash flow-€51.92M+41.6% YoY
Operating cash flow-€43.91M

Revenue, last 8 quarters

€221.2MDec '24€200.0MMar '25€171.2MJun '25€163.9MSep '25€253.3MDec '25€156.6MMar '26€143.5MJun '26€164.9MSep '26

Net profit, last 8 quarters

€-40.8MDec '24€-31.6MMar '25€-43.5MJun '25€-43.1MSep '25€14.6MDec '25€-121.9MMar '26€-46.6MJun '26€-26.7MSep '26

Profitability & balance sheet

Gross margin10.3%
Operating margin-17.5%
Net margin-25.2%
Return on equity-25.1%
Return on assets-11.0%
Return on invested capital-14.5%
Current ratio2.32
Liabilities / assets57.4%
Cash & investments€418.48M
Total debt€417.21M
Net cash (debt)€1.27M

Discussion

No comments yet — be the first to weigh in on EVO.

Sign in to join the discussion.

Scroll to Top